½ÃÀ庸°í¼­
»óǰÄÚµå
1542632

¼¼°èÀÇ ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¿¹Ãø(2024-2032³â)

Global Biopharmaceutical Excipients Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 131 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 31¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â ¾à 53¾ï 2,000¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ 2024-2032³âÀÇ CAGRÀº 6.12%·Î ¿¹»óµË´Ï´Ù.

¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦´Â ¹é½Å, ´ÜŬ·ÐÇ×ü, À¯ÀüÀÚ Ä¡·á µîÀÇ ¹ÙÀÌ¿À ÀǾàǰÀ» Á¦ÇüÈ­ÇÏ´Â ºÒȰ¼º ¹°ÁúÀÔ´Ï´Ù. À¯È¿¼ººÐÀÇ ¾ÈÁ¤È­, ¿ëÇØ¼ºÀÇ Çâ»ó, ¾à¹°Àü´ÞÀÇ °³¼± µî, ´Ù¾çÇÑ ±â´ÉÀ» ¿Ï¼öÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ã·°¡Á¦´Â ¾ÈÁ¤Á¦, º¸Á¸Á¦, ¿ëÇØÁ¦ µîÀÇ ¹°ÁúÀ» Æ÷ÇÔÇϸç, ¹ÙÀÌ¿À ÀǾàǰÀÇ È¿´É, ¾ÈÀü¼º ¹× ǰÁúÀ» È®º¸Çϴµ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ±âÁ¸ÀÇ ÀǾàǰ¿¡ »ç¿ëµÇ´Â ÷°¡Á¦¿Í ´Þ¸® ÀǾàǰ Ȱ¼º ¼ººÐ(API)ÀÇ »ý¹°ÇÐÀû Ȱ¼ºÀ» ÀúÇØÇÏÁö ¾Êµµ·Ï ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç ¹× ÀûÇÕ¼º ±âÁØÀ» ÃæÁ·ÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

»ý¹° Á¦Á¦¿Í ÷´Ü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À ÀǾàǰ ºÎ¹®ÀÌ È®´ëµÊ¿¡ µû¶ó »ý¹° Á¦Á¦ÀÇ ¾ÈÁ¤¼º, Àü´Þ ¹× È¿´ÉÀ» ³ôÀ̱âÀ§ÇÑ Æ¯¼ö ÷°¡Á¦ÀÇ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÷°¡Á¦´Â ´ÜÀÏŬ·Ð Ç×ü ¹× À¯ÀüÀÚ Ä¡·á¿Í °°Àº º¹ÀâÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Á¦ÇüÈ­¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϸç, Á¦Ç°ÀÇ Ç°Áú°ú ¼º´ÉÀ» À¯ÁöÇϱâ À§Çؼ­´Â °¢°¢¿¡ ¸Â´Â ÷°¡Á¦ ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÷°¡Á¦ °³¹ßÀÇ ±â¼ú Áøº¸´Â ½ÃÀå¿¡ Å« ±âȸ¸¦ °¡Á®¿Ô½À´Ï´Ù. »õ·Î¿î ¾ÈÁ¤Á¦ ¹× °í±Þ Àü´Þ ½Ã½ºÅÛ°ú °°Àº ÷°¡Á¦ ±â¼úÀÇ Çõ½ÅÀº ¹ÙÀÌ¿À ÀǾàǰÀÇ Á¦ÇüÈ­ ¹× Á¦Á¶¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â º¸´Ù È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ä¡·áÀÇ °³¹ßÀ» °¡´ÉÇÏ°Ô Çϰí ÷´Ü ÷°¡Á¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ¶ÇÇÑ ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °³ÀÎÈ­ Ä¡·á¿¡´Â Á¾Á¾ Á¦ÇüÀÇ µ¶Æ¯ÇÑ °úÁ¦¸¦ ÇØ°áÇÏ°í ¾à¹° Àü´ÞÀ» ÃÖÀûÈ­Çϱâ À§ÇØ Æ¯¼ö ÷°¡Á¦°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ Ãß¼¼´Â ¼ºÀåÇÏ´Â °³ÀÎÈ­µÈ ÀÇ·á ºÎ¹®À» Áö¿øÇϱâ À§ÇØ ¸ÂÃãÇü ÷°¡Á¦ ¼Ö·ç¼ÇÀÇ °³¹ßÀ» ÃËÁøÇÕ´Ï´Ù. ±ÔÁ¦ÀÇ ÁøÀü°ú ǰÁú °ü¸®ÀÇ Á߽à Áõ°¡°¡ ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀ» ´õ¿í °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÌ ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶¿¡ ¾ö°ÝÇÑ ÁöħÀ» ºÎ°úÇÏ´Â µ¿¾È ÷°¡Á¦ÀÇ Ç°Áú°ú ÄÄÇöóÀ̾𽺿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀ» ÃæÁ·Çϰí Á¦Ç°ÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» º¸ÀåÇϴ ÷°¡Á¦ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº R&D ºñ¿ë°ú ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ ¼³¹® Á¶»ç º¸°í¼­´Â Porter's Five Force ¸ðµ¨, ½ÃÀå ¸Å·Â ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØÀÇ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ µµ±¸´Â ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ Á¢±Ù¹ýÀ» ¼³¸íÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡°¡ °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» ÆÄ¾ÇÇϰí ÇâÈÄ ±âȸ¸¦ Áö¿øÇÕ´Ï´Ù.

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÁßÁ¡À» µÓ´Ï´Ù.

¸ÂÃ㠿䱸»çÇ×ÀÌ ÀÖ´Â °æ¿ì ´ç»ç¿¡ ¹®ÀÇÇϼ¼¿ä. ´ç»çÀÇ ¼³¹®Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦-¾÷°è ºÐ¼®

  • ¼Ò°³: ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü À϶÷
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀ̾î À϶÷
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ¼¼°è ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • Á¦Ç°º° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • °¡¿ëÁ¦ ¹× °è¸éȰ¼ºÁ¦/À¯È­Á¦(Æ®¸®±Û¸®¼¼¸®µå, ¿¡½ºÅ׸£ µî)
  • Æú¸®¿Ã(¸¶´ÏÅç, ¼Ò¸£ºñÅç, ±âŸ)
  • ź¼öÈ­¹°(ÀÚ´ç, Æ÷µµ´ç, ÀüºÐ, ±âŸ)

Á¦6Àå ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼Ò°³
  • ºÏ¹Ì ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´: ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç: ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«: ±¹°¡º° À϶÷
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦7Àå ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ±â¾÷°æÀï ±¸µµ

  • ¹ÙÀÌ¿À ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ °æÀï
  • Á¦ÈÞ, Çù·Â, ÇùÁ¤
  • ÇÕº´ ¹× Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦8Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Merck KGaA
  • Colorcon
  • BASF SE
  • Associated British Foods Plc
  • Signet Excipients Pvt. Ltd(IMCD)
  • Sigachi Industries Limited
  • Spectrum Chemical Manufacturing Corp.
  • Roquette FreRes
  • IMCD
  • Clariant
  • DFE Pharma
  • J. Rettenmaier & SoHne GmbH Co KG
  • Evonik Industries AG
JHS 24.09.24

The global demand for Biopharmaceutical Excipients Market is presumed to reach the market size of nearly USD 5.32 Billion by 2032 from USD 3.12 Billion in 2023 with a CAGR of 6.12% under the study period 2024-2032.

Biopharmaceutical excipients are inert substances that formulate biopharmaceutical products, such as vaccines, monoclonal antibodies, and gene therapies. They serve various functions, including stabilizing active ingredients, enhancing solubility, and improving drug delivery. These excipients can include substances like stabilizers, preservatives, and solubilizers, and are crucial in ensuring the efficacy, safety, and quality of biopharmaceuticals. Unlike excipients used in traditional pharmaceuticals, they must meet stringent regulatory requirements and compatibility standards to ensure they do not interfere with the biological activity of the active pharmaceutical ingredients (APIs).

Market Dynamics

The increasing demand for biologics and advanced therapeutics drives the biopharmaceutical excipients market. As the biopharmaceutical sector expands, there is a growing need for specialized excipients to enhance biologic drugs' stability, delivery, and efficacy. Excipients play an integral role in formulating complex biologics, such as monoclonal antibodies & gene therapies, which require tailored excipient solutions to maintain product quality and performance. Technological advancements in excipient development are creating significant opportunities within the market. Innovations in excipient technologies, such as novel stabilizers and advanced delivery systems, are improving the formulation and manufacturing of biopharmaceutical products. These advancements enable the development of more effective and safer therapeutics, driving demand for cutting-edge excipients.

The increasing focus on personalized medicine also contributes to biopharmaceutical excipients market growth. Personalized therapeutics often require specialized excipients to address unique formulation challenges and optimize drug delivery. This trend is driving the development of customized excipient solutions to support the growing field of personalized medicine. Regulatory advancements and a growing emphasis on quality control further drive the biopharmaceutical excipients market. As regulatory agencies impose stricter guidelines for biopharmaceutical manufacturing, there is a heightened focus on excipient quality and compliance. This has led to increased investment in the development of excipients that meet rigorous regulatory standards and ensure product safety and efficacy. However, high research and development costs and stringent regulatory requirements may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Biopharmaceutical Excipients. The growth and trends of Biopharmaceutical Excipients industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Biopharmaceutical Excipients market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Solubilizes & Surfactants/Emulsifiers (Triglycerides, Esters, Others)
  • Polyols (Mannitol, Sorbitol, Others)
  • Carbohydrates (Sucrose, Dextrose, Starch, Others)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Biopharmaceutical Excipients market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Biopharmaceutical Excipients market include Merck KGaA, Colorcon, BASF SE, Associated British Foods Plc, Signet Excipients Pvt. Ltd (IMCD), Sigachi Industries Limited, Spectrum Chemical Manufacturing Corp., Roquette FreRes, IMCD, Clariant, DFE Pharma, J. Rettenmaier & SoHne GmbH + Co KG, Evonik Industries AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. BIOPHARMACEUTICAL EXCIPIENTS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Solubilizes & Surfactants/Emulsifiers (Triglycerides, Esters, Others) Historic and Forecast Sales By Regions
  • 5.4. Polyols (Mannitol, Sorbitol, Others) Historic and Forecast Sales By Regions
  • 5.5. Carbohydrates (Sucrose, Dextrose, Starch, Others) Historic and Forecast Sales By Regions

6. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET ANALYSIS BY GEOGRAPHY

  • 6.1. Regional Outlook
  • 6.2. Introduction
  • 6.3. North America Sales Analysis
    • 6.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 6.3.2 North America By Segment Sales Analysis
    • 6.3.3 North America By Country Sales Analysis
    • 6.3.4 United States Sales Analysis
    • 6.3.5 Canada Sales Analysis
    • 6.3.6 Mexico Sales Analysis
  • 6.4. Europe Sales Analysis
    • 6.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 6.4.2 Europe By Segment Sales Analysis
    • 6.4.3 Europe By Country Sales Analysis
    • 6.4.4 United Kingdom Sales Analysis
    • 6.4.5 France Sales Analysis
    • 6.4.6 Germany Sales Analysis
    • 6.4.7 Italy Sales Analysis
    • 6.4.8 Russia Sales Analysis
    • 6.4.9 Rest Of Europe Sales Analysis
  • 6.5. Asia Pacific Sales Analysis
    • 6.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 6.5.2 Asia Pacific By Segment Sales Analysis
    • 6.5.3 Asia Pacific By Country Sales Analysis
    • 6.5.4 China Sales Analysis
    • 6.5.5 India Sales Analysis
    • 6.5.6 Japan Sales Analysis
    • 6.5.7 South Korea Sales Analysis
    • 6.5.8 Australia Sales Analysis
    • 6.5.9 South East Asia Sales Analysis
    • 6.5.10 Rest Of Asia Pacific Sales Analysis
  • 6.6. Latin America Sales Analysis
    • 6.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 6.6.2 Latin America By Segment Sales Analysis
    • 6.6.3 Latin America By Country Sales Analysis
    • 6.6.4 Brazil Sales Analysis
    • 6.6.5 Argentina Sales Analysis
    • 6.6.6 Peru Sales Analysis
    • 6.6.7 Chile Sales Analysis
    • 6.6.8 Rest of Latin America Sales Analysis
  • 6.7. Middle East & Africa Sales Analysis
    • 6.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 6.7.2 Middle East & Africa By Segment Sales Analysis
    • 6.7.3 Middle East & Africa By Country Sales Analysis
    • 6.7.4 Saudi Arabia Sales Analysis
    • 6.7.5 UAE Sales Analysis
    • 6.7.6 Israel Sales Analysis
    • 6.7.7 South Africa Sales Analysis
    • 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE BIOPHARMACEUTICAL EXCIPIENTS COMPANIES

  • 7.1. Biopharmaceutical Excipients Market Competition
  • 7.2. Partnership/Collaboration/Agreement
  • 7.3. Merger And Acquisitions
  • 7.4. New Product Launch
  • 7.5. Other Developments

8. COMPANY PROFILES OF BIOPHARMACEUTICAL EXCIPIENTS INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Market Concentration Rate
  • 8.3. Merck KGaA
    • 8.3.1 Company Overview
    • 8.3.2 Company Revenue
    • 8.3.3 Products
    • 8.3.4 Recent Developments
  • 8.4. Colorcon
    • 8.4.1 Company Overview
    • 8.4.2 Company Revenue
    • 8.4.3 Products
    • 8.4.4 Recent Developments
  • 8.5. BASF SE
    • 8.5.1 Company Overview
    • 8.5.2 Company Revenue
    • 8.5.3 Products
    • 8.5.4 Recent Developments
  • 8.6. Associated British Foods Plc
    • 8.6.1 Company Overview
    • 8.6.2 Company Revenue
    • 8.6.3 Products
    • 8.6.4 Recent Developments
  • 8.7. Signet Excipients Pvt. Ltd (IMCD)
    • 8.7.1 Company Overview
    • 8.7.2 Company Revenue
    • 8.7.3 Products
    • 8.7.4 Recent Developments
  • 8.8. Sigachi Industries Limited
    • 8.8.1 Company Overview
    • 8.8.2 Company Revenue
    • 8.8.3 Products
    • 8.8.4 Recent Developments
  • 8.9. Spectrum Chemical Manufacturing Corp.
    • 8.9.1 Company Overview
    • 8.9.2 Company Revenue
    • 8.9.3 Products
    • 8.9.4 Recent Developments
  • 8.10. Roquette FreRes
    • 8.10.1 Company Overview
    • 8.10.2 Company Revenue
    • 8.10.3 Products
    • 8.10.4 Recent Developments
  • 8.11. IMCD
    • 8.11.1 Company Overview
    • 8.11.2 Company Revenue
    • 8.11.3 Products
    • 8.11.4 Recent Developments
  • 8.12. Clariant
    • 8.12.1 Company Overview
    • 8.12.2 Company Revenue
    • 8.12.3 Products
    • 8.12.4 Recent Developments
  • 8.13. DFE Pharma
    • 8.13.1 Company Overview
    • 8.13.2 Company Revenue
    • 8.13.3 Products
    • 8.13.4 Recent Developments
  • 8.14. J. Rettenmaier & SoHne GmbH + Co KG
    • 8.14.1 Company Overview
    • 8.14.2 Company Revenue
    • 8.14.3 Products
    • 8.14.4 Recent Developments
  • 8.15. Evonik Industries AG
    • 8.15.1 Company Overview
    • 8.15.2 Company Revenue
    • 8.15.3 Products
    • 8.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦